Pacira BioSciences, Inc. (PCRX): Price and Financial Metrics

Pacira BioSciences, Inc. (PCRX)

Today's Latest Price: $33.05 USD

1.05 (3.28%)

Updated Apr 7 10:36am

Add PCRX to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 214 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

PCRX Stock Summary

  • With a one year PEG ratio of 287.6, Pacira BioSciences Inc is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than 89.72% of US stocks.
  • Price to trailing twelve month operating cash flow for PCRX is currently 18.04, higher than 83.33% of US stocks with positive operating cash flow.
  • Revenue growth over the past 12 months for Pacira BioSciences Inc comes in at 24.83%, a number that bests 80.76% of the US stocks we're tracking.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Pacira BioSciences Inc are AVLR, GRUB, SMAR, AXTI, and LC.
  • PCRX's SEC filings can be seen here. And to visit Pacira BioSciences Inc's official web site, go to
PCRX Daily Price Range
PCRX 52-Week Price Range

PCRX Stock Price Chart More Charts

PCRX Price/Volume Stats

Current price $33.05 52-week high $51.35
Prev. close $32.00 52-week low $27.46
Day low $32.58 Volume 73,637
Day high $33.62 Avg. volume 668,056
50-day MA $39.89 Dividend yield N/A
200-day MA $41.13 Market Cap 1.39B

Pacira BioSciences, Inc. (PCRX) Company Bio

Pacira Pharmaceuticals develops, commercializes, and manufactures proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the United States. The company was founded in 2006 and is based in Parsippany, New Jersey.

PCRX Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target:Forecasted Gain:

Below please find a table outlining a discounted cash flow forecast for PCRX, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Pacira BioSciences Inc ranked in the 76th percentile in terms of potential gain offered. Moreover, under all the scenarios we modelled, the output consistently forecasted positive returns. As for the metrics that stood out in our discounted cash flow analysis of Pacira BioSciences Inc, consider:

  • Its compound free cash flow growth rate, as measured over the past 4.99 years, is 0.76% -- higher than 89.14% of stocks in our DCF forecasting set.
  • Pacira BioSciences Inc's interest coverage rate -- a measure of gross earnings relative to interest payments -- comes in at 0.55. This coverage rate is greater than that of only 21.73% of stocks we're observing for the purpose of forecasting via discounted cash flows.
  • The weighted average cost of capital for the company is 9. This value is greater than 80.47% stocks in the Healthcare sector that generate free cash flow.

Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price

Want more companies with a valuation profile/forecast similar to that of Pacira BioSciences Inc? See CI, INVA, CCEL, CVS, and ABC.

PCRX Latest News Stream

Event/TimeNews Detail
Loading, please wait...

PCRX Latest Social Stream

Loading social stream, please wait...

View Full PCRX Social Stream

PCRX Price Returns

1-mo -17.62%
3-mo -23.32%
6-mo -10.12%
1-year -17.13%
3-year -28.39%
5-year -62.25%
YTD -27.04%
2019 5.30%
2018 -5.76%
2017 41.33%
2016 -57.94%
2015 -13.39%

Continue Researching PCRX

Want to see what other sources are saying about Pacira BioSciences Inc's financials and stock price? Try the links below:

Pacira BioSciences Inc (PCRX) Stock Price | Nasdaq
Pacira BioSciences Inc (PCRX) Stock Quote, History and News - Yahoo Finance
Pacira BioSciences Inc (PCRX) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8168 seconds.